

3. (Amended) The method of claim 1 wherein the composition further comprises a growth factor selected from the group consisting of FGF-1, TGF- β 1, and TGF- β 3.

4. (Amended) The method of claim 1 wherein the growth factors are derived from a natural source and are at least partially phosphorylated and glycosylated.

5. (Amended) The method of claim 1, wherein said composition is free of histone proteins H1c and H1x.

6. (Amended) The method of claim 1 wherein said composition comprises a mixture of growth factors comprising BMP-2, BMP-3, BMP-6, and TGF- β 2 in a pharmaceutically acceptable carrier.

7. (Amended) The method of claim 1 wherein said composition is substantially free of ribosomal proteins LORP, Lg, s20, L3, S3a, S4 and L32.

8. (Amended) The method of claim 1 wherein said growth factors are derived from bovine bone and are at least partially phosphorylated and glycosylated.

9. (Amended) A composition for the treatment of wounds, said composition comprising a histone-depleted mixture of proteins comprising a bone-derived protein cocktail which, when subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis, yields a reduced or non-reduced protein band profile as indicated in Figure 1, said bone-derived protein cocktail having been treated to remove histone proteins, said composition including a pharmaceutically acceptable carrier.

10. (Amended) The composition of claim 9, wherein said histone-depleted mixture of proteins has been further treated to remove ribosomal proteins.

11. (Amended) A composition for the treatment of wounds, said composition comprising a ribosome-depleted mixture of proteins comprising a bone-derived protein cocktail which, when

A1
C1
subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis, yields a reduced or non-reduced protein band profile as indicated in Figure 1, said bone-derived protein cocktail having been treated to remove ribosomal proteins, said composition including a pharmaceutically acceptable carrier.

12. (Amended) The composition of claim 11, wherein said ribosome-depleted mixture of proteins has been further treated to remove histone proteins.

A2
13. (Amended) A composition for the treatment of wounds, said composition comprising a mixture of proteins comprising BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, TGF- β 1, TGF- β 2, TGF- β 3, FGF-1 in a pharmaceutically acceptable carrier.

A2
16. (Amended) The composition of claim 13, wherein said proteins have been isolated from a natural source and are at least partially phosphorylated and glycosylated.

17. (Amended) The composition of claim 13, wherein at least one of said proteins is a recombinantly produced protein.

A2
18. (Amended) A method of promoting wound healing, said method comprising applying a composition as in claim 13 to a wound.

Please add new claims 25 and 26, as follows:

A2
25. (New) A method of promoting wound closure comprising applying to said wound a composition comprising a bone-derived mixture of phosphorylated and glycosylated proteins which, when subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis, yields a reduced or non-reduced protein band pattern as identified in Figure 1, from which protein mixture ribosomal proteins and/or histone proteins have been removed, said composition including a pharmaceutically acceptable carrier.